Edgewise Therapeutics Stock

edgewisetx.comHealthcareFounded: 2017Funding to Date: $65.5MM

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need.

Register for Details

For more details on financing and valuation for Edgewise Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Edgewise Therapeutics.

Register Today

Team

Management Team

Kevin Koch
Chief Executive Officer, President & Board Member
Alan Russell Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Peter Thompson MD
Co-Founder & Chairman
Badreddin Edris Ph.D
Co-Founder & Board Observer

Board Members

Alan Russell Ph.D
Peter Thompson MD
Jonathan Root MD
US Venture Partners
Kenneth Harrison Ph.D
Novo Holdings
Badreddin Edris Ph.D
Robert Jackson MD
Deerfield Management

Other companies like Edgewise Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B

News

Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, closed a $50m Series B financing